Akari Therapeutics | 8-K: Current report
Akari Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer DICICCO WENDY F
Akari Therapeutics | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
Akari Therapeutics | 8-K: Current report
Akari Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Jacques Rachelle Suzanne
Akari Therapeutics | 8-K: Current report
Akari Therapeutics | 8-K: Current report
Akari Therapeutics | 10-K: Annual report
Akari Therapeutics | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
Akari Therapeutics | 8-K: Current report
Akari Therapeutics | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
Akari Therapeutics | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
Akari Therapeutics | 8-K: Current report
Akari Therapeutics | D: Filing D
Akari Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ray Prudo, M.D.(26.4%),RPC Pharma Limited(6.1%), etc.
Akari Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Jacques Rachelle Suzanne
Akari Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer DICICCO WENDY F
Akari Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Patel Samir Rashmikant
Akari Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Hashad Mohamed Wa'el Ahmed
Akari Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Prudo-Chlebosz Raymond
No Data